Advanced search
Publication Cover
Biomarkers in Medicine Volume 1, 2007 - Issue 4
Submit an article Journal homepage
78
Views
0
CrossRef citations to date
0
Altmetric
Review

B-Type Natriuretic Peptides in Heart Failure: Update on Clinical Applications and Limitations

Wayne L Miller1 Mayo Clinic,Divisions of Cardiovascular Diseases,College of Medicine & Foundation,200 First Street, SW,Rochester,MN55905,USA.Correspondence[email protected]
,
Paul V Targonski2 Mayo Clinic,Primary Care Internal Medicine,College of Medicine & Foundation,200 First Street, SW,Rochester,MN55905,USA.Correspondence[email protected]
&
Allan S Jaffe1 Mayo Clinic,Divisions of Cardiovascular Diseases,College of Medicine & Foundation,200 First Street, SW,Rochester,MN55905,USA.Correspondence[email protected]
Pages 503-512 | Published online: 17 Dec 2007

Bibliography

  • Koglin J , PehlivanliS, SchwablmairM, VogesserM, CremerP, vonScheidtW: Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure.J. Am. Coll. Cardiol.38, 1934–1941 (2001).
  • Wang TJ , LarsonMG, LevyDet al.: Plasma natriuretic peptide levels and the risk of cardiovascular events and death.N. Engl. J. Med.350, 655–663 (2004).
  • Wu AHB , PackerM, SmithAet al.: Analytical and clinical evaluation of the Bayer ADVIA Centaur automated B-type natriuretic peptide assay in patients with heart failure: a multisite study.Clin. Chem.50(5), 867–873 (2004).
  • Biosite Inc. Triage BNP package insert. Biosite Inc (Ed.), San Diego, CA, USA (2002).
  • Forfia PR , WatkinsSP, RameJE, StewartKJ, ShapiroEP: Relationship between B-type natriuretic peptides and pulmonary capillary wedge pressure in the intensive care unit.J. Am. Coll. Cardiol.45, 1667–1671 (2005).
  • Maisel AS , McCordJ, NowakRMet al.: Bedside B-type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. results from the Breathing Not Properly Multinational Study.J. Am. Coll. Cardiol.41, 2010–2017 (2003).
  • Cheng V , KazanagraR, GarciaAet al.: A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study.J. Am. Coll. Cardiol.37, 386–391 (2001).
  • Miller WL , HartmanKA, BurrittMF, BorgesonDD, BurnettJCJr, JaffeAS: Biomarker responses during and after treatment with nesiritide in patients with decompensated chronic heart failure.Clin. Chem.51, 569–577 (2005).
  • Hawkridge AM , HeubleinDM, BergenHR, CataliottiA, BurnettJC, MuddimanDC: Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure.Proc. Natl Acad. Sci. USA102(48), 17442–17447 (2005).
  • Seferian KR , TammNN, SemenovAG et al: The brain natriuretic peptide (BNP) precursor is the major immunoreactive form of BNP in patients with heart failure. Clin. Chem.53(5), 866–873 (2007).
  • Lam CSP , BurnettJC, Costello-BoerrigterL, RodehefferRJ, RedfieldMM: Alternate circulating pro-B-type natriuretic peptide and B-type natriuretic peptide forms in the general population.J. Am. Coll. Cardiol.49, 1193–1202 (2007).
  • Liang F , O‘RearJ, SchellenbergerUet al.: Evidence of functional heterogeneity of circulating B-type natriuretic peptide.J. Am. Coll. Cardiol.49, 1071–1078 (2007).
  • Ala-Kopsala M , MaggaJ, PeuhkurinenKet al.: Molecular heterogeneity has a major impact on the measurement of circulating N-terminal fragments of A and B-type natriuretic peptides.Clin. Chem.50(9), 1576–1588 (2004).
  • Jaffe AS , AppleFS, BabuinL: Why we don‘t know the answer may be more important than the specific question.Clin. Chem.50(9), 1495–1497 (2004).
  • Goetze JP : Biochemistry of pro-B-type natriuretic peptide-derived peptides: the endocrine heart revisited.Clin. Chem.50, 1503–1510 (2004).
  • Clerico A , EmdinM: Diagnostic accuracy and prognostic relevance of the measurements of cardiac natriuretic peptides: a review.Clin. Chem.50, 33–50 (2004).
  • Schou M , DalsgaardMK, ClemmesenOet al.: Kidneys extract BNP and NT-proBNP in healthy young men.J. Appl. Physiol.99, 1676–1680 (2005).
  • Goetze JP , JensenG, MollerS, BendtsenF, RehfeldJF, HenriksenJH: BNP and N-terminal proBNP are both extracted in the normal kidney.Eur. J. Clin. Invest.36, 8–15 (2006).
  • Olsen MH , WachtellK, TuxenCet al.: N-terminal pro-brain natriuretic peptide predicts cardiovascular events in patients with hypertension and left ventricular hypertrophy: a LIFE study.J. Hypertens.22, 1597–1604 (2004).
  • Kucher N , PrintzenG, GoldhaberSZ: Prognostic role of brain natriuretic peptide in acute pulmonary embolism.Circulation107, 2545–2547 (2003).
  • Kruger S , GrafJ, MerxMWet al.: Brain natriuretic peptide predicts right heart failure in patients with acute pulmonary embolism.Am. Heart J.147, 60–65 (2004).
  • Gerber IL , StewartRA, LeggetMEet al.: Increased plasma natriuretic peptide levels reflect symptom onset in aortic stenosis.Circulation107, 1884–1890 (2003).
  • deLemos JA , MorrowDA, BentleyJHet al.: The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes.N. Engl. J. Med.345, 1014–1021 (2001).
  • Lindahl B , LindbackJ, JernbergTet al.: Serial analyses of N-terminal pro-B-type natriuretic peptide in patients with non-ST-segment elevation acute coronary syndromes.J. Am. Coll. Cardiol.45, 533–541 (2005).
  • Richards M , NichollsMG, EspinerEAet al.: Comparison of B-type natriuretic peptides for assessment of cardiac function and prognosis in stable ischemic heart disease.J. Am. Coll. Cardiol.47, 52–60 (2006).
  • McCullough PA , Gabriel StegP, Aumont MP for the BNP Multinational Study Investigators: What causes elevated B-type natriuretic peptide in patients without heart failure?J. Am. Coll. Cardiol.41, 278A (2003).
  • Shor R , RozenmanY, BolshinskyAet al.: BNP in septic patients without systolic myocardial dysfunction.Eur. J. Intern. Med.17, 536–540 (2006).
  • Brueckmann M , HuhleG, LangSet al.: Prognostic value of plasma N-terminal pro-brain natriuretic peptide in patients with severe sepsis.Circulation112, 527–534 (2005).
  • Redfield MM , RodehefferRJ, JacobsenSJ, MahoneyDW, BaileyKR, BurnettJCJr: Plasma brain natriuretic peptide to detect preclinical ventricular systolic and diastolic dysfunction. A community-based study.Circulation109, 3176–3181 (2004).
  • Lubien E , DemariaA, KrishnaswamyPet al.: Utility of B-natriuretic peptide in detecting diastolic dysfunction. Comparison with Doppler velocity recordings.Circulation105, 595–601 (2002).
  • Babuin L , AlegriaJR, OhJK, NishimuraRA, JaffeAS: Brain natriuretic peptide levels in constrictive pericarditis and restrictive cardiomyopathy.J. Am. Coll. Cardiol.47, 1489–1491 (2006).
  • Leya FS , ArabD, JoyalDet al.: The efficacy of brain natriuretic peptide levels in differentiating constrictive pericarditis from restrictive cardiomyopathy. J. Am. Coll. Cardiol.45, 1900–1902 (2005).
  • Knudsen CW , CloptonP, WestheimAet al.: Predictors of elevated B-type natriuretic peptide concentrations in dyspneic patients without heart failure: an analysis from the Breathing Not Properly multinational study.Ann. Emerg. Med.45, 573–580 (2005).
  • Shapiro BP , ChenHH, BurnettJCJr, RedfieldMM: Use of plasma brain natriuretic peptide concentration to aid in the diagnosis of heart failure.Mayo Clin. Proc.78, 481–486 (2003).
  • Redfield MM , RodehefferRJ, JacobsenSJ, MahoneyDW, VaileyKR, BurnettJCJr: Plasma brain natriuretic peptide concentration: impact of age and gender.J. Am. Coll. Cardiol.40, 976–982 (2002).
  • Kawai K , HataK, TanakaKet al.: Attenuation of biologic compensatory action of cardiac natriuretic peptide system with aging. Am. J. Cardiol.93, 719–723 (2004).
  • Bursi F , WestonSA, RedfieldMAet al.: Systolic and diastolic heart failure in the community. JAMA296, 2209–2216 (2006).
  • Chang AY , AbdullahSM, JainTet al.: Associations between androgens, estrogens, and natriuretic peptides in young women: observations from the Dallas Heart Study. J. Am. Coll. Cardiol.49, 109–116 (2007).
  • Wang TJ , LarsonMG, LevyDet al.: Impact of obesity on plasma natriuretic peptide levels. Circulation109, 594–600 (2004).
  • Das SR , DraznerMH, DriesDLet al.: Impact of body mass and body composition of circulating levels of natriuretic peptides. Results of the Dallas Heart Study. Circulation112, 2163–2168 (2005).
  • Mehra MR , UberPA, ParkMHet al.: Obesity and suppressed B-type natriuretic peptide levels. J. Am. Coll. Cardiol.43, 1590–1595 (2004).
  • McCord J , MundyBJ, HudsonMPet al.: Relationship between obesity and B-type natriuretic peptide levels. Arch. Intern. Med.164, 2247–2252 (2004).
  • Horwich TB , HamiltonMA, FonarowGC: B-type natriuretic peptide levels in obese patients with advanced heart failure.J. Am. Coll. Cardiol.47, 85–90 (2006).
  • Hermann-Arnhof K -M, Hanusch-Enserer U, Kaestenbauer T et al.: N-terminal pro-B-type natriuretic peptide as an indicator of possible cardiovascular disease in severely obese individuals: comparison with patients in different stages of heart failure. Clin. Chem.51, 138–143 (2005).
  • Rivera M , CortesR, SalvadorAet al.: Obese subjects with heart failure have lower N-terminal pro-brain natriuretic peptic plasma levels irrespective of etiology. Eur. J. Heart Fail.7, 1168–1170 (2005).
  • Anwaruddin S , Lloyd-JonesDM, BaggishAet al.: Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement (PRIDE study). J. Am. Coll. Cardiol.47, 91–97 (2006).
  • Tsutamoto T , WadeA, SakaiHet al.: Relationship between renal function and plasma brain natriuretic peptide in patients with heart failure. J. Am. Coll. Cardiol.47, 582–586 (2006).
  • Cataliotti A , MalatinoLS, JougasakiMet al.: Circulating natriuretic peptide concentrations in patients with end-stage renal disease: role of brain natriuretic peptide as a biomarker of ventricular remodeling. Mayo Clin. Proc.76, 1111–1119 (2001).
  • Luchner A , BurnettJCJr, JougasakiM, HenseHW, RieggerGA, SchunkertH: Augmentation of the cardiac natriuretic peptides by β-receptor antagonism: evidence from a population-based study.J. Am. Coll. Cardiol.32, 1839–1844 (1998).
  • Davis ME , RichardsAM, NichollsMG, YandleTG, FramptonCM, TroughtonRW: Introduction of metoprolol increases plasma B-type cardiac natriuretic peptides in mild, stable heart failure.Circulation113, 977–985 (2006).
  • Takeda Y , FukutomiT, SuzukiSet al.: Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction. Am. J. Cardiol.94, 448–453 (2004).
  • Mueller C , ScholerA, Laule-KilianKet al.: Use of B-Type natriuretic peptide in the evaluation and management of acute dyspnea. N. Engl. J. Med.350, 647–654 (2004).
  • Januzzi JL , CamargoCA, AnwaruddinSet al.: The N-Terminal Pro-BNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. Am. J. Cardiol.95, 948–954 (2005).
  • Chen AA , WoodMJ, KrauserDGet al.: NT-proBNP levels, echocardiographic findings, and outcomes in breathless patients: results from the ProBNP Investigation of Dyspnoea in the Emergency Department (PRIDE) echocardiographic substudy. Eur. Heart J.27, 839–845 (2006).
  • Vasan RS , BenjaminEJ, LarsonMGet al.: Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction. The Framingham Study. JAMA288, 1252–1259 (2002).
  • Costello-Boerrigter LC , BoerrigterG, RedfieldMMet al.: Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. J. Am. Coll. Cardiol.47, 345–353 (2006).
  • Logeart D , ThabutG, JourdainPet al.: Pre-discharge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J. Am. Coll. Cardiol.43, 635–641 (2004).
  • Wu AHB , SmithA, AppleFS: Optimum blood collection intervals for B-type natriuretic peptide testing in patients with heart failure.Am. J. Cardiol.93, 1562–1563 (2004).
  • Anand IS , FisherLD, Yann-TongCet al.: Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation107, 1278–1283 (2003).
  • Miller WL , BurnettJCJr, HartmanKA, HenleMP, BurrittMF, JaffeAS: Lower rather than higher Levels of B-type natriuretic peptides predict short-term mortality in end-stage heart failure patients treated with nesiritide.Am. J. Cardiol.96, 837–841 (2005).
  • Knudsen CW , OmlandT, CloptenPet al.: Impact of atrial fibrillation on the diagnostic performance of B-type natriuretic peptide concentration in dyspneic patients: an analysis from the Breathing Not Properly multinational study.J. Am. Coll. Cardiol.46, 838–844 (2005).
  • Bettencourt P , AzevedoA, PimentaJ, FrioesF, FerreiraS, FerreiraA: N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients.Circulation110, 2168–2174 (2004).
  • Troughton RW , FramptonCM, YandleTG, EspinerTG, NichollsMG, RichardAM: Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations.Lancet355, 1126–1130 (2000).
  • Jourdain P , JondeauG, FunckFet al.: Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure – The STARS-BNP multicenter study. J. Am. Coll. Cardiol.49, 1733–1739 (2007).
  • Moe GW , HowlettJ, JanuzziJL, ZowallH, IMPROVE-CHF study investigators: N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure.Circulation115, 3103–3110 (2007).
  • Shah MR : STARBRITE: a randomized pilot trial of BNP-guided therapy in patients with advanced heart failure (abstract).Circulation114(Suppl. 2, 18), 2556 (2006).
  • Lainchbury JG , TroughtonRW, FramptonCMet al.: NTproBNP-guided drug treatment for chronic heart failure: design and methods in the ‘BATTLESCARRED‘ trial.Eur. J. Heart Fail.5, 532–538 (2006).
  • Brunner-LaRocca HP , BuserPT, SchindlerR, BernheimA, RickenbackerP, Pfisterer M for the TIME-CHF Investigators: Management of elderly patients with congestive heart failure-design of the trial of intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF).Am. Heart J.151, 949–955 (2006).
  • Rodeheffer RJ : Measuring plasma B-type natriuretic peptide in heart failure. Good to go in 2004?J. Am. Coll. Cardiol.44, 740–749 (2004).
  • Mueller T , GegenhuberA, DieplingerB, PoelzW, HaltmayerM: Long-term stability of endogenous B-type natriuretic peptide (BNP) and amino terminal proBNP (NT-proBNP) in frozen plasma samples.Clin. Chem. Lab. Med.42, 942–944 (2004).
  • Januzzi JL , van KimmenadeR, LainchburyJet al.: NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients.Eur. Heart J.27, 330–337 (2006).
  • Wu AHB , SmithA, WieczorekSet al.: Biological variation for N-terminal pro- and B-type natriuretic peptide and implications for therapeutic monitoring of patients with congestive heart failure.Am. J. Cardiol.92, 628–631 (2003).
  • Wu AHB : Serial testing of B-type natriuretic peptide and NT-pro-BNP for monitoring therapy of heart failure: the role of biologic variation in the interpretation of results.Am. Heart J.152, 828–834 (2006).
  • Araujo JP , AzevedoA, LourencoP, Rocha-GoncalvesF, FerreiraA, BettencourtP: Intraindividual variation of amino-terminal pro-B-type natriuretic peptide levels in patients with stable heart failure.Am. J. Cardiol.98, 1248–1250 (2006).
  • Gegenhuber A , MuellerT, FirlingerF, LenzK, PoelzW, HaltmayerM: Time course of B-type natriuretic peptide (BNP) and N-terminal proBNP changes in patients with decompensated heart failure.Clin. Chem.50(2), 454–456 (2004).
  • Adams KF , LindenfeldJ, ArnoldJMOet al.: Executive Summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline.J. Card. Fail.12(1), 10–38 (2006).
  • ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult. J. Am. Coll. Cardiol. 46, 1116–1143 (2005).
  • ESC Guidelines on the diagnosis and treatment of acute heart failure. The Task Force on Acute Heart Failure of the European Society of Cardiology. Eur. Heart J. 26, 384–416 (2005).
  • Giuliani I , RieunierF, LarueCet al.: Assay for measurement of intact B-type natriuretic peptide prohormone in blood.Clin. Chem.52, 1054–1061 (2006).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.